Session (CTI)

PURPOSE: Health technology developers (HTDs) currently use early cost-effectiveness models to determine economically justifiable prices (EJPs) based on target product profiles (TPPs). These are then used to evaluate future commercial decisions, such as whether to move forward with development or how to optimize launch. Whilst this analysis provides important insights, a major limitation is only being able to evaluate a single TPP at a time. This workshop demonstrates a novel methodology, termed Value-Based Decision Boundary Analysis (VB-DBA), which enables practitioners to use network meta-analysis to determine minimum TPP requirements that satisfy different decision-making criteria and give rise to a range of EJPs. Attendees will learn how to utilize and deploy this methodology to support early commercial feasibility assessments for their assets. DESCRIPTION: Attendees will learn how to implement VB-DBA and the value of this type of analysis. Workshop contents include a review of existing approaches and challenges, detailed VB-DBA methodology and execution, and the relevance to HTDs. Ronan Mahon will moderate the session and introduce the topic in the context of drug development (8 minutes). This will include real-time audience polling regarding HEOR approaches currently in use during early asset assessments. Subhajit Gupta will provide a detailed walkthrough of statistical methods, data requirements and assumptions required to deploy these methods (20 mins). George Joseph and Kokuvi Atsou will illustrate how these methods are being used in drug development and how they may affect launch strategy in practice (10 mins each). Additional audience participation will include identifying challenges and solutions for a hypothetical case study in renal cell carcinoma (7 mins). This will form a worked example presented by Ronan Mahon. The final 5 minutes will be audience questions and feedback. This interactive informative workshop will be valuable to researchers, pharmaceutical executives and health economic/evidence synthesis analysts interested in combined health economic/evidence synthesis methods required for decision-making within early phase drug development.